{
  "id": "PK_CYP2C9_INHIB_WARFARIN",
  "name": "CYP2C9 inhibition increases warfarin exposure and bleeding risk",
  "domain": "PK",
  "severity": "major",
  "rule_class": "adjust_monitor",
  "tags": ["exposure_increase"],
  "actions": [
    "Consider a non-interacting alternative when possible (educational).",
    "If coadministered, emphasize closer INR monitoring.",
    "Counsel regarding signs of bleeding."
  ],
  "logic": {
    "enzyme": {
      "id": "CYP2C9",
      "A_role": "substrate",
      "B_role": "inhibitor"
    },
    "A_ti": "narrow",
    "rationale": [
      "Warfarin has a narrow therapeutic index.",
      "CYP2C9 is an important clearance pathway for warfarin.",
      "Reduced clearance can increase anticoagulant effect and bleeding risk."
    ]
  },
  "explanation_template": "{B_name} inhibits CYP2C9 and {A_name} is a CYP2C9 substrate with a narrow therapeutic index. This can increase anticoagulant effect and bleeding risk.",
  "references": [
    {
      "source": "Educational note",
      "citation": "High-risk pattern: narrow therapeutic index substrate plus metabolic inhibition."
    }
  ]
}
